Ideaya Biosciences Financials
IDYA Stock | USD 21.37 0.92 4.13% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 9.62 | 14.9707 |
|
|
The financial analysis of Ideaya Biosciences is a critical element in measuring its lifeblood. Investors should not minimize Ideaya Biosciences' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Ideaya | Select Account or Indicator | Build AI portfolio with Ideaya Stock |
Understanding current and past Ideaya Biosciences Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Ideaya Biosciences' financial statements are interrelated, with each one affecting the others. For example, an increase in Ideaya Biosciences' assets may result in an increase in income on the income statement.
Please note, the presentation of Ideaya Biosciences' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ideaya Biosciences' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Ideaya Biosciences' management manipulating its earnings.
Ideaya Biosciences Stock Summary
Ideaya Biosciences competes with AnaptysBio, MeiraGTx Holdings, Keros Therapeutics, Ventyx Biosciences, and Protagonist Therapeutics. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. Ideaya Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 91 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US45166A1025 |
CUSIP | 45166A102 |
Location | California; U.S.A |
Business Address | 5000 Shoreline Court, |
Sector | Biotechnology |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.ideayabio.com |
Phone | 650 443 6209 |
Currency | USD - US Dollar |
Ideaya Biosciences Key Financial Ratios
Return On Equity | -0.31 | ||||
Operating Margin | (51.48) % | ||||
Price To Sales | 267.38 X | ||||
Revenue | 7 M | ||||
Gross Profit | (315.75 M) |
Ideaya Biosciences Key Balance Sheet Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Total Assets | 298.3M | 381.3M | 388.0M | 649.3M | 1.1B | 1.2B | |
Other Current Liab | 7.0M | 17.3M | 25.0M | 18.8M | 30.1M | 31.6M | |
Other Liab | 34K | 56.2M | 31.2M | 5.2M | 6.0M | 5.7M | |
Net Tangible Assets | 100.4M | 198.3M | 301.5M | 349.5M | 401.9M | 422.0M | |
Net Debt | (65.3M) | (86.9M) | (65.2M) | (154.1M) | (65.2M) | (68.5M) | |
Retained Earnings | (127.0M) | (176.7M) | (235.4M) | (348.4M) | (622.8M) | (591.7M) | |
Accounts Payable | 953K | 2.1M | 4.3M | 6.6M | 15.4M | 16.2M | |
Cash | 72.0M | 92.0M | 68.6M | 157.0M | 84.4M | 73.5M | |
Other Assets | 122K | 188K | 397K | 205K | 184.5K | 239.2K | |
Capital Surpluse | 192.8M | 325.3M | 479.0M | 587.7M | 675.9M | 709.7M | |
Other Current Assets | 6.3M | 6.2M | 5.4M | 7.5M | 13.4M | 14.1M | |
Total Liab | 298.3M | 381.3M | 388.0M | 28.2M | 64.9M | 61.7M | |
Net Invested Capital | 198.3M | 301.5M | 349.5M | 621.1M | 1.1B | 1.1B | |
Total Current Assets | 288.6M | 251.0M | 370.5M | 532.6M | 689.7M | 724.2M | |
Net Working Capital | 250.0M | 205.8M | 338.7M | 505.5M | 643.6M | 675.8M | |
Short Term Debt | 3.1M | 3.4M | 3.7M | 1.7M | 596K | 566.2K | |
Common Stock | 3K | 4K | 5K | 7K | 9K | 9.5K | |
Capital Stock | 3K | 4K | 5K | 7K | 9K | 4.7K |
Ideaya Biosciences Key Income Statement Accounts
2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
Net Interest Income | 849K | 506K | 3.8M | 21.5M | 52.5M | 55.1M | |
Interest Income | 849K | 506K | 3.8M | 21.5M | 52.5M | 55.1M | |
Interest Expense | 849K | 506K | 3.8M | 21.5M | 24.7M | 25.9M | |
Total Revenue | 19.5M | 27.9M | 50.9M | 23.4M | 7M | 6.7M | |
Gross Profit | 19.5M | 27.9M | 50.9M | 19.4M | 3.2M | 3.0M | |
Operating Income | (35.3M) | (50.3M) | (62.5M) | (134.4M) | (327.0M) | (310.6M) | |
Ebit | (35.3M) | (50.3M) | (62.5M) | (134.4M) | (121.0M) | (114.9M) | |
Research Development | 39.7M | 58.2M | 89.5M | 129.5M | 294.7M | 309.4M | |
Ebitda | (34.0M) | (48.5M) | (60.4M) | (130.4M) | (327.0M) | (310.6M) | |
Cost Of Revenue | 39.7M | 1.7M | 2.1M | 4.0M | 3.8M | 7.4M | |
Income Before Tax | (34.5M) | (49.8M) | (58.7M) | (113.0M) | (274.5M) | (260.8M) | |
Net Income | (32.3M) | (47.5M) | (54.8M) | (113.0M) | (274.5M) | (260.8M) | |
Income Tax Expense | (2.2M) | (2.2M) | (3.8M) | 3.8M | 4.4M | 4.6M |
Ideaya Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Ideaya Biosciences's current stock value. Our valuation model uses many indicators to compare Ideaya Biosciences value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Ideaya Biosciences competition to find correlations between indicators driving Ideaya Biosciences's intrinsic value. More Info.Ideaya Biosciences is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Ideaya Biosciences' Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Ideaya Biosciences' earnings, one of the primary drivers of an investment's value.Ideaya Biosciences Systematic Risk
Ideaya Biosciences' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Ideaya Biosciences volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Ideaya Biosciences correlated with the market. If Beta is less than 0 Ideaya Biosciences generally moves in the opposite direction as compared to the market. If Ideaya Biosciences Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Ideaya Biosciences is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Ideaya Biosciences is generally in the same direction as the market. If Beta > 1 Ideaya Biosciences moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Ideaya Biosciences Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Ideaya Biosciences' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Ideaya Biosciences growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Ideaya Biosciences June 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Ideaya Biosciences help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Ideaya Biosciences. We use our internally-developed statistical techniques to arrive at the intrinsic value of Ideaya Biosciences based on widely used predictive technical indicators. In general, we focus on analyzing Ideaya Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Ideaya Biosciences's daily price indicators and compare them against related drivers.
Downside Deviation | 4.15 | |||
Information Ratio | 0.0702 | |||
Maximum Drawdown | 23.99 | |||
Value At Risk | (4.90) | |||
Potential Upside | 6.69 |
Complementary Tools for Ideaya Stock analysis
When running Ideaya Biosciences' price analysis, check to measure Ideaya Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ideaya Biosciences is operating at the current time. Most of Ideaya Biosciences' value examination focuses on studying past and present price action to predict the probability of Ideaya Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ideaya Biosciences' price. Additionally, you may evaluate how the addition of Ideaya Biosciences to your portfolios can decrease your overall portfolio volatility.
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Stocks Directory Find actively traded stocks across global markets | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |